Skip to search formSkip to main contentSkip to account menu

Celsentri

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
PRODUCT INFORMATION CELSENTRI ( maraviroc ) NAME OF THE MEDICINE
PRODUCT INFORMATION CELSENTRI (maraviroc) NAME OF THE MEDICINE CELSENTRI 150 mg and 300 mg film-coated tablets. CELSENTRI film… 
2010
2010
Does HIV infection enhance the hepatocarcinogenic potential of chronic hepatitis B virus infection?
Review
2009
Review
2009
[CCR5 antagonists: a new class of antiretrovirals].
A decade after identification of the chemokine receptor CCR5 as a coreceptor for human immunodeficiency virus (HIV), the first… 
2009
2009
All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.
2009
2009
96-Week MERIT ES analysis shows efficacy of Celsentri=Selzentry.
Review
2008
Review
2008
How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals.
2008
2008
Maraviroc (Celsentri) in HIV treatment
Since 1996, the prognosis of people living with immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) has… 
2008
2008
Métodos de determinación del tropismo viral: tests genotípicos y fenotípicos
2007
2007
Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
(1) Maraviroc belongs to a new class of antiretroviral drugs designed to block entry of HIV-1 into CD4+ T-cells via the CCR5… 
Review
2007
Review
2007
Antiretroviral treatment of HIV infection: Swedish recommendations 2007
On 3 previous occasions, in 2002, 2003 and 2005, the Swedish Medical Products Agency (Läkemedelsverket) and the Swedish Reference… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)